TR200102038T2 - Amid bileşenler - Google Patents
Amid bileşenlerInfo
- Publication number
- TR200102038T2 TR200102038T2 TR2001/02038T TR200102038T TR200102038T2 TR 200102038 T2 TR200102038 T2 TR 200102038T2 TR 2001/02038 T TR2001/02038 T TR 2001/02038T TR 200102038 T TR200102038 T TR 200102038T TR 200102038 T2 TR200102038 T2 TR 200102038T2
- Authority
- TR
- Turkey
- Prior art keywords
- bond
- formula
- alkylene
- amide components
- singlet
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title 1
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- -1 amide compounds Chemical class 0.000 abstract 1
- 230000001713 cholinergic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP8180A AUPP818099A0 (en) | 1999-01-14 | 1999-01-14 | New n-containing heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200102038T2 true TR200102038T2 (tr) | 2002-01-21 |
Family
ID=3812385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2001/02038T TR200102038T2 (tr) | 1999-01-14 | 2000-01-06 | Amid bileşenler |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6710043B1 (enExample) |
| EP (1) | EP1140836B1 (enExample) |
| JP (2) | JP3617454B2 (enExample) |
| KR (2) | KR100525809B1 (enExample) |
| CN (1) | CN1142910C (enExample) |
| AR (1) | AR028812A1 (enExample) |
| AT (1) | ATE502923T1 (enExample) |
| AU (1) | AUPP818099A0 (enExample) |
| BR (1) | BRPI0008753B8 (enExample) |
| CA (1) | CA2360360C (enExample) |
| CZ (1) | CZ20012562A3 (enExample) |
| DE (1) | DE60045759D1 (enExample) |
| ES (1) | ES2363492T3 (enExample) |
| HK (1) | HK1044337B (enExample) |
| HU (1) | HU230422B1 (enExample) |
| IL (2) | IL143841A0 (enExample) |
| RU (1) | RU2208608C2 (enExample) |
| TR (1) | TR200102038T2 (enExample) |
| TW (1) | TWI229075B (enExample) |
| WO (1) | WO2000042011A1 (enExample) |
| ZA (1) | ZA200104713B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6344358B1 (en) * | 1999-05-28 | 2002-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
| UY27003A1 (es) | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
| JPWO2002045715A1 (ja) * | 2000-12-07 | 2004-04-08 | 藤沢薬品工業株式会社 | 抗痴呆効果増強剤 |
| WO2003049736A1 (en) * | 2001-12-11 | 2003-06-19 | Sepracor, Inc. | 4-substituted piperidines, and methods of use thereof |
| CN100340167C (zh) * | 2002-12-06 | 2007-10-03 | 陶氏农业科学公司 | 增效组合物 |
| WO2004089296A2 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| CA2559665A1 (en) | 2004-03-16 | 2005-09-29 | The Regents Of The University Of California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| NZ554555A (en) | 2004-10-20 | 2011-09-30 | Univ California | Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase |
| CA2579227A1 (en) * | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Arylalkyl ureas as cb1 antagonists |
| ES2348332T3 (es) | 2005-09-16 | 2010-12-02 | Arrow Therapeutics Limited | Derivados de bifenilo y su uso en el tratamiento de la hepatitis c. |
| AR059826A1 (es) * | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| US8247442B2 (en) | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
| US8791264B2 (en) | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| WO2007118854A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
| JP2010507587A (ja) * | 2006-10-20 | 2010-03-11 | アレテ セラピューティクス， インコーポレイテッド | 可溶性エポキシドヒドロラーゼ阻害剤 |
| WO2008051873A2 (en) * | 2006-10-20 | 2008-05-02 | Arete Therapeutics, Inc. | Phenylurea compounds as soluble epoxide hydrolase inhibitors |
| GB0706793D0 (en) * | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| US8637544B2 (en) | 2007-04-20 | 2014-01-28 | Senju Pharmaceutical Co., Ltd. | Neurite formation promoter |
| WO2009040659A2 (en) | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| SI2207775T1 (sl) | 2007-11-05 | 2012-05-31 | Novartis Ag | benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza |
| EP2404901B1 (en) | 2007-12-03 | 2013-05-22 | Novartis AG | 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| US8946197B2 (en) | 2009-11-16 | 2015-02-03 | Chdi Foundation, Inc. | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2012054093A2 (en) | 2010-01-29 | 2012-04-26 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| US8889716B2 (en) | 2011-05-10 | 2014-11-18 | Chdi Foundation, Inc. | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4939679B1 (enExample) | 1969-06-30 | 1974-10-28 | ||
| US3647805A (en) * | 1969-07-11 | 1972-03-07 | Kyorin Seiyaku Kk | Benzoylamino substituted 1-benzoyl-piperidines |
| BE791501A (fr) | 1971-11-19 | 1973-05-17 | Albert Ag Chem Werke | Diamines cycliques n,n'-disubstituees et leur procede de preparation |
| GB1416872A (en) | 1972-03-10 | 1975-12-10 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
| JPS5152176A (enExample) | 1974-10-12 | 1976-05-08 | Yoshitomi Pharmaceutical | |
| EP0002401B1 (fr) | 1977-11-24 | 1980-12-10 | Synthelabo | Dérivés de naphtalène, leur préparation et leur application en thérapeutique |
| DE3544244A1 (de) * | 1985-12-14 | 1987-06-25 | Minnesota Mining & Mfg | Vorrichtung zum entnehmen von fuellgut aus beuteln |
| US4886809A (en) | 1986-07-31 | 1989-12-12 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof |
| CA1322199C (en) | 1987-07-15 | 1993-09-14 | Masami Eigyo | N-¬(2-oxopyrrolidin-1-yl) acetyl)| piperazine derivatives and drug for senile dementia |
| JPH0696575B2 (ja) * | 1987-09-17 | 1994-11-30 | 三菱化成株式会社 | ４−アミノピリジン誘導体及びその酸付加塩 |
| US5346907A (en) * | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
| GB8917687D0 (en) | 1989-08-02 | 1989-09-20 | Fujisawa Pharmaceutical Co | Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
| RU2024507C1 (ru) * | 1991-11-18 | 1994-12-15 | Евгений Яковлевич Левитин | 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность |
| CA2077252C (en) | 1992-08-31 | 2001-04-10 | Khashayar Karimian | Methods of making ureas and guanidines, and intermediates therefor |
| US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
| ATE219766T1 (de) * | 1993-04-07 | 2002-07-15 | Otsuka Pharma Co Ltd | N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen |
| CA2123728A1 (en) | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
| DE4319038A1 (de) | 1993-06-08 | 1994-12-15 | Bayer Ag | Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung |
| KR100324040B1 (ko) * | 1993-06-18 | 2002-07-22 | 후지사와 야꾸힝 고교 가부시키가이샤 | 합성적 용도로 사용하기 위한 신규한 중간체 및아미노피페라진유도체를제조하는방법 |
| US5500423A (en) | 1994-09-09 | 1996-03-19 | Hoechst-Roussel Pharmaceuticals Inc. | 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines |
| IL117805A0 (en) | 1995-04-07 | 1996-08-04 | Schering Corp | Carbonyl piperazinyl and piperidinyl compounds |
| GB9519077D0 (en) * | 1995-09-18 | 1995-11-15 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| EP0873117A4 (en) | 1995-11-13 | 1999-02-24 | Smithkline Beecham Corp | HEMOREGULATORY CONNECTIONS |
| FR2744449B1 (fr) * | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
| ZA9710872B (en) | 1996-12-12 | 1998-06-15 | Fujisawa Pharmaceutical Co | N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate. |
| WO1998027930A2 (en) | 1996-12-24 | 1998-07-02 | Fujisawa Pharmaceutical Co., Ltd. | New use of aminopiperazine derivatives |
| WO1998035951A2 (en) | 1997-02-17 | 1998-08-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminopiperazine derivatives |
| US6344358B1 (en) * | 1999-05-28 | 2002-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
-
1999
- 1999-01-14 AU AUPP8180A patent/AUPP818099A0/en not_active Abandoned
- 1999-12-27 TW TW088123003A patent/TWI229075B/zh not_active IP Right Cessation
-
2000
- 2000-01-06 KR KR10-2001-7007314A patent/KR100525809B1/ko not_active Expired - Lifetime
- 2000-01-06 KR KR10-2004-7009661A patent/KR100520406B1/ko not_active Expired - Lifetime
- 2000-01-06 US US09/869,962 patent/US6710043B1/en not_active Expired - Lifetime
- 2000-01-06 HK HK02105923.9A patent/HK1044337B/zh not_active IP Right Cessation
- 2000-01-06 CZ CZ20012562A patent/CZ20012562A3/cs unknown
- 2000-01-06 ES ES00900121T patent/ES2363492T3/es not_active Expired - Lifetime
- 2000-01-06 EP EP00900121A patent/EP1140836B1/en not_active Expired - Lifetime
- 2000-01-06 TR TR2001/02038T patent/TR200102038T2/xx unknown
- 2000-01-06 CA CA002360360A patent/CA2360360C/en not_active Expired - Lifetime
- 2000-01-06 BR BRPI0008753A patent/BRPI0008753B8/pt not_active IP Right Cessation
- 2000-01-06 HU HU0105108A patent/HU230422B1/hu not_active IP Right Cessation
- 2000-01-06 IL IL14384100A patent/IL143841A0/xx active IP Right Grant
- 2000-01-06 RU RU2001122727/04A patent/RU2208608C2/ru active
- 2000-01-06 CN CNB008027455A patent/CN1142910C/zh not_active Expired - Lifetime
- 2000-01-06 AT AT00900121T patent/ATE502923T1/de active
- 2000-01-06 DE DE60045759T patent/DE60045759D1/de not_active Expired - Lifetime
- 2000-01-06 JP JP2000593579A patent/JP3617454B2/ja not_active Expired - Lifetime
- 2000-01-06 WO PCT/JP2000/000017 patent/WO2000042011A1/en not_active Ceased
- 2000-01-12 AR ARP000100123A patent/AR028812A1/es not_active Application Discontinuation
-
2001
- 2001-06-08 ZA ZA200104713A patent/ZA200104713B/en unknown
- 2001-06-19 IL IL143841A patent/IL143841A/en not_active IP Right Cessation
-
2003
- 2003-05-12 JP JP2003132491A patent/JP2004002414A/ja not_active Withdrawn
- 2003-07-15 US US10/618,743 patent/US20040014745A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200102038T2 (tr) | Amid bileşenler | |
| HUP9903766A2 (en) | Pyridyl alkene- and pyridyl alkine- acid amides, use of them as cytostatics and immunosuppressives, process for their preparation and pharmaceuticals containing the same | |
| EP0970954A4 (en) | 3-PIPERIDYL-4-OXOCHINAZOLINE DERIVATIVES AND MEDICAL COMPOSITIONS CONTAINING THEM | |
| MX9709951A (es) | Derivados de benzamida y su uso como antagonistas de vasopresina. | |
| TR200100075T2 (tr) | 2-Kuinolon ihtiva eden farmasötik bileşimler | |
| DE69507293D1 (de) | Benzamid-derivate als vasopressin-antagonisten | |
| PT928788E (pt) | Compostos farmaceuticamente activos | |
| AP9701039A0 (en) | Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one. | |
| ATE289602T1 (de) | Quinolin-2-on-derivate verwendbar als antikrebsmittel | |
| MX9306831A (es) | Nuevos compuestos heterociclicos. | |
| AP9801169A0 (en) | N-hydroxy-B-sulfonyl propionamide derivatives. | |
| WO1998035951A3 (en) | New aminopiperazine derivatives | |
| AP9801378A0 (en) | 9-amino-3- keto erythromycin derivatives. | |
| TR200200789T2 (tr) | Farmasötik olarak aktif sülfonamid türevleri. | |
| AU643282B2 (en) | Liposomes with positive excess charge | |
| FR2442845A1 (fr) | Derives amines spiranniques, leur preparation et leur utilisation comme medicaments | |
| TR199801782T2 (xx) | Kinoksalindionlar | |
| EA200100983A1 (ru) | Производные 13-метилэритромицина | |
| NO924929L (no) | Farmasoeytisk aktive benzoquinazolinforbindelser | |
| IL114785A0 (en) | Pyrrolocarbazoles their preparation and pharmaceutical compositions containing them | |
| EA200300044A1 (ru) | Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции | |
| TR200200125T2 (tr) | Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar. | |
| DE68926981D1 (de) | Cephemverbindungen und Verfahren zu ihrer Herstellung | |
| ATE86866T1 (de) | Antikrebs-zusammensetzung. | |
| BG103197A (bg) | Антитромботични азациклоалкилалканоил пептиди и псевдопептиди |